Weekly Watched Assets — 2026-04-05
4 high-conviction US stocks identified from monthly sentiment analysis.
AMT — American Tower Corporation
1W +3.2% | 1M -1.9% | 3M +6.4% | YTD +2.6%
"rare contrarian opportunity"
Thesis: AMT presents a rare contrarian opportunity driven by a deep market disconnect and aggressive mispricing, with a clear path to re-rating catalyzed by the Q1 2026 earnings call and validation of its GPU-as-a-Service model. The thesis is backed by institutional-grade conviction language and a strong margin of safety, supporting asymmetric risk/reward. Conviction: 96% (high)
BILI — Bilibili
1W +3.1% | 1M -6.9% | 3M -18.6% | YTD -9.9%
"compelling value story"
Thesis: Bilibili offers a compelling value proposition trading at a 48% discount to fair value with strong earnings growth visibility and a confirmed catalyst from Apple's reduced iOS commission. Citi's Buy upgrade and evidence of insider buying reinforce the inflection in sentiment, despite weak near-term price momentum. Conviction: 96% (high)
TAK — Takeda Pharmaceutical Company Limited
1W -3.5% | 1M -0.2% | 3M +10.8% | YTD +15.8%
"game-changer for TAK’s neuroscience pipeline"
Thesis: Takeda's neuroscience pipeline, led by rusfertide, presents a de-risked catalyst with significant re-rating potential ahead of an FDA decision in Q3 2026, supported by clear undervaluation and asymmetric risk/reward. However, near-term price weakness and lower momentum compared to peers temper urgency. Conviction: 96% (high)
ZS — Zscaler Inc. Common Stock
1W -14.8% | 1M -23.2% | 3M -45.5% | YTD -46.5%
"deep-value opportunity—but one haunted by deep market skepticism"
Thesis: Zscaler is deeply undervalued with a 32.8% gap to fair value and strong customer adoption momentum, yet faces intense market skepticism and severe recent drawdowns across all timeframes, reflecting high execution and sentiment risk. The Z-Flex program provides a tangible catalyst, but macro and AI-disruption fears cloud near-term clarity. Conviction: 95% (high)